India · Delayed Price · Currency is INR Rossari Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Q4 and FY 2026 saw record revenue and EBITDA, with 15% annual growth driven by all segments and strong exports. FY 2027 guidance targets similar or higher growth and 12%-13% EBITDA margins, supported by new capacities, product mix improvements, and cost optimization.
-
Q3 FY26 saw 13% YoY revenue growth, led by strong export performance and broad-based segment gains, though margins were impacted by ongoing investments and B2C weakness. New capacities and global expansion, especially in Saudi Arabia, are set to drive future growth and margin improvement.
-
Q2 FY 2026 saw 18% revenue growth, led by strong volumes across all core segments and robust export gains, though margins softened due to pricing pressures and one-time expenses. Capacity expansions and new product launches support a positive outlook, but global tariffs and working capital stretch pose risks.
-
Q1 FY26 saw 11% YoY revenue growth, led by HPPC and AHN, with EBITDA margin at 12.5%. Capacity expansions and international initiatives are underway, with mid-double-digit growth and margin improvement expected as new facilities ramp up and export headwinds ease.
Fiscal Year 2025
-
FY 2025 delivered 13.6% revenue growth and stable margins, driven by HPPC and new verticals, with strong export momentum. CapEx of INR 192 crores will expand capacity and support innovation, while margin improvement is expected as new businesses scale.
-
Q3 FY25 saw 10.5% YOY revenue growth to INR 512.7 crore, led by strong exports and improved gross margins, though EBITDA margin declined due to higher costs from expansion and hiring. Capacity additions and export growth are expected to drive future performance, with EO supply a key risk.